Search - tctmd.com

Displaying 1 - 11 of 11

Sort: Relevancy | Date

Earlier Evolocumab Cut CVD, CV Mortality Over Longer Term: FOURIER-OLE

News Conference News ESC 2022

Earlier Evolocumab Cut CVD, CV Mortality Over Longer Term: FOURIER-OLE

Michael O'Riordan

August 31, 2022

Novel Targets, Gene Edits, and Vaccines: Is a ‘Golden Era’ Dawning for ASCVD?

News Features

Novel Targets, Gene Edits, and Vaccines: Is a ‘Golden Era’ Dawning for ASCVD?

Michael O'Riordan

August 15, 2022

Genetic Study Hints at Cognitive Impact of Statins, but Experts Urge Caution

News Daily News

Genetic Study Hints at Cognitive Impact of Statins, but Experts Urge Caution

Michael O'Riordan

August 11, 2022

FH Patients Face Unchanging Acute MI Risks Plus Very Late Diagnoses

News Conference News EAS 2022

FH Patients Face Unchanging Acute MI Risks Plus Very Late Diagnoses

Michael O'Riordan

May 26, 2022

ROSE Trial: CETP Inhibitor Shows Promise as Oral Add-on for LDL-Lowering

News Conference News EAS 2022

ROSE Trial: CETP Inhibitor Shows Promise as Oral Add-on for LDL-Lowering

Michael O'Riordan

May 24, 2022

Stepwise or Hammer Down? Experts Debate Best Approach to LDL-Lowering

News Conference News EAS 2022

Stepwise or Hammer Down? Experts Debate Best Approach to LDL-Lowering

Michael O'Riordan

May 24, 2022

Good News and Bad for High-Intensity Statin Use in ASCVD

News Daily News

Good News and Bad for High-Intensity Statin Use in ASCVD

Michael O'Riordan

May 05, 2022

SCAI-Led Position Statement on CLTI Spotlights Multispeciality Involvement

News Daily News

SCAI-Led Position Statement on CLTI Spotlights Multispeciality Involvement

April 27, 2022

Pelacarsen Targets Lp(a), With Little Impact on LDL Cholesterol

News Daily News

Pelacarsen Targets Lp(a), With Little Impact on LDL Cholesterol

Michael O'Riordan

March 15, 2022

Absence of CAC May be Protective Even in Patients With Very High Cholesterol

News Daily News

Absence of CAC May be Protective Even in Patients With Very High Cholesterol

Michael O'Riordan

February 14, 2022

Pricey Inclisiran Is Rolling Out: a ‘Buy-and-Bill’ Model May Smooth Its Path

News Features

Pricey Inclisiran Is Rolling Out: a ‘Buy-and-Bill’ Model May Smooth Its Path

Michael O'Riordan

January 17, 2022

Country

First Name

Last Name

Email

Profession

Organization

Country

CAPTCHA

This question is for testing whether or not you are a human visitor and to prevent automated spam submissions.